Screening for Occult Malignancy in Patients with Unprovoked Venous Thromboembolism
Embolism and ThrombosisVenous thromboembolism (VTE) can be the earliest sign of cancer. Identifying occult cancers at the time of VTE diagnosis may lead to significant improvement of patients' care. This is also an upmost issue for patients who want to know if an underlying cancer might have triggered the VTE.
An individual patient-level data meta-analysis (IPDMA) supports extensive screening strategies for occult cancer especially based on FDG PET/CT, and suggests that the best target population for cancer screening would be patients with unprovoked VTE older than 50 years of age (6.7% in patients aged 50 years or more vs. 1.0% in patients of less than 50 years (OR: 7.1, 95% CI: 3.1 to 16%).
null
Conditions de participation
-
Sexe:
ALL -
Âges admissibles:
50 and up
Critères de participation
Inclusion Criteria:
Patients aged 50 years or older with a new diagnosis of first unprovoked proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) will be eligible to participate into the study.
Unprovoked VTE is defined as the absence of any of the following predisposing factors:
1. active malignancy (known malignancy, progressive and/or treated during the last 5 years) except for adequately treated basal or squamous cell carcinoma; Patients whose state of health suggests the presence of cancer at the time of diagnosis of VTE cannot be included in the protocol
2. recent (less than 3 months) paralysis, paresis or plaster immobilization of the lower extremities;
3. recently bedridden for period of 3 or more days, or major surgery, within the previous 12 weeks requiring general or regional anaesthesia;
4. previous unprovoked VTE;
5. known thrombophilia (hereditary or acquired)
Exclusion Criteria:
Patients will be excluded from the study if they have any of the following criteria:
1. Refusal or inability to provide informed consent;
2. Hypersensitivity to 18F-FDG or any of the excipients according to the product monograph;
3. Unavailable to follow-up.
4. VTE while on anticoagulation (e.g apixaban, rivaroxaban, edoxaban, dabigatran, warfarin)
Lieu de l'étude
McMaster University
McMaster UniversityHamilton, Ontario
Canada
Contactez l'équipe d'étude
Deborah Siegal
Sunnybrook Research Institute
Sunnybrook Research InstituteToronto, Ontario
Canada
Contactez l'équipe d'étude
Jean-Phillippe Galanaud
University of Manitoba
University of ManitobaWinnipeg, Manitoba
Canada
Contactez l'équipe d'étude
Ryan Zarychanski
Ottawa Hospital Research Institute
Ottawa Hospital Research InstituteOttawa, Ontario
Canada
Contactez l'équipe d'étude
Grégoire LE GAL
McGill University Health Centre
McGill University Health CentreMontréal, Quebec
Canada
Contactez l'équipe d'étude
Susan Solymoss
London Health Sciences Centre
London Health Sciences CentreLondon, Ontario
Canada
Contactez l'équipe d'étude
Alejandro Lazno-Langner
University Health Network
University Health NetworkToronto, Ontario
Canada
Contactez l'équipe d'étude
Jameel Abdulrehman
Erik Yeo
University of Calgary
University of CalgaryCalgary, Alberta
Canada
Contactez l'équipe d'étude
Leslie Skeith
Hopital Montfort
Hopital MontfortOttawa, Ontario
Canada
Contactez l'équipe d'étude
Gregoire Le Gal
Jewish General Hospital
Jewish General HospitalMontréal, Quebec
Canada
Contactez l'équipe d'étude
Vicky Tagalakis
- Étude parrainée par
- University Hospital, Brest
- Participants recherchés
- Plus d'informations
- ID de l'étude:
NCT04304651